SLC5A2 and chronic kidney disease: Similarly, SGLT2 inhibitors, such as empagliflozin, canagliflozin, and dapagliflozin, have demonstrated significant benefits in reducing intraglomerular pressure, improving renal outcomes, and reducing cardiovascular events in patients with CKD, irrespective of diabetic status.